← Back to patent-cliff list
亚胺西瑞
Tier C — Watch / tradeCilastatin Sodium/Imipenem/Relebactam
默沙东
Originator
2019
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Beta Lactamase、Enzymes、PBPs
Brand：锐可博、Recarbrio
Indications (approved)：细菌性肺炎、医院获得性肺炎、传染性疾病、菌血症、呼吸机相关性肺炎、医疗保健相关性肺炎、革兰氏阴性细菌感染、腹腔感染
Regional status
US
批准上市
2019-07-16
EU
批准上市
2020-02-13
China
批准上市
2024-12-01
Japan
批准上市
2021-06-23
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cilastatin Sodium/Imipenem/Relebactam?
Approved indications include: 细菌性肺炎, 医院获得性肺炎, 传染性疾病, 菌血症, 呼吸机相关性肺炎, 医疗保健相关性肺炎, 革兰氏阴性细菌感染, 腹腔感染.
When does the Cilastatin Sodium/Imipenem/Relebactam patent expire?
No public expiry year is available for Cilastatin Sodium/Imipenem/Relebactam yet; this page updates once verified.
How do I get a quote for Cilastatin Sodium/Imipenem/Relebactam intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24